Equity Details
Price & Market Data
Price: $0.155
Daily Change: -$0.0328 / 21.11%
Daily Range: $0.155 - $0.155
Market Cap: $112,168,815
Daily Volume: 5,000
Performance Metrics
1 Week: -17.43%
1 Month: -17.43%
3 Months: -17.43%
6 Months: -35.41%
1 Year: -41.73%
YTD: -17.43%
About Brii Biosciences Limited (BRIBF)
In-depth market report for Brii Biosciences Limited (BRIBF). The stock is valued at 0.155, with a daily change of -$0.0328 / 21.11%. Market cap: 112,168,815. All key performance metrics are updated, including YTD and 52-week returns.
Company Details
Employees: 75
Sector: Health technology
Industry: Biotechnology
Country: China
Details
Brii Biosciences Limited focuses on developing therapies for the treatment of infectious and central nervous system diseases in China and the United States. The company develops BRII-179, a recombinant protein-based HBV immunotherapeutic candidate; Elebsiran, an investigational subcutaneously administered HBV-targeting siRNA; and Tobevibart, an investigational subcutaneously administered HBV-neutralizing monoclonal antibody which are in Phase 2 of the development stage for functional cure of HBV for Hepatitis B; and BRII-732 that has completed Phase 1 clinical trial and BRII-753, which is in preclinical stage for the treatment of HIV. It also develops BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative bacterial infections, which has completed Phase 1; and Epetraborole for oral treatment for patients with chronic NTM lung disease. Brii Biosciences Limited was incorporated in 2017 and is headquartered in Beijing, China.
